I agree. The list is tough but fair...
I still see
I agree. The list is tough but fair...
I still see through a tiny window of opportunity in our CD-12 extension. The FDA wouldn’t of granted us an extension unless they hoped they would get us to an EUA. So please explain the reasoning that they would give us an extension for any other reason? It’s like they said... well 62 patients and iffy results don’t add up to enough confidence for us to take it to my boss and then their boss to seek an EUA. If we knocked it out of the park with 62 people... ok... let’s argue about it.
I find it reassuring that the FDA gave us this opportunity to improve our results and achieve efficacy and trial strength for our CD-15 trial. That’s huge in my book. They could of done so much worse. Tell to start over. Raise our patient count to a 1000. Yet here we stand complaining about anything and everything from the past. Not that there isn’t everyone’s right to complain.
My thoughts are did we hit 70 people and what day was that so we can count down the 28 days and then estimate the ability to gather the information on those people. If it happened a week or two ago that we hit 55 people then have we hit 70 already this past week? When do we start the clock on the fastest way for us to achieve an EUA? Is Nader going to update us on the 70 people they deemed necessary to achieve EUA? Is Nader playing this card close to his chest for nobody to see? Or will he say we have hit that number now and in 28 days we will have those great results we talked about in the 16.7% mortality. Sometimes we just have to read between the lines. The lines can be blurry.
The quickest approval for EUA in the USA is this journey I just laid out for us. It’s not over on the CD-12 trial just yet. We have not been turned down. We have been told to show us better results in an extension and we will consider you. That is another chance to set the age gap evenly and to somehow average the rather higher than normal placebo mortality that nobody expected. If our 70 patients average results to more normal expectations. Then we are in great shape in my opinion.
This is our big chance and some of you just can’t see it. Let hope the extension is our first of many successes.
It is for the benefit of all of us to take a step back and see the big picture of what is transpiring. There has to be a reason we haven’t broken down the door on a new protocol after having one submitted and approved then we just tread water for what? It’s like throwing pasta at the wall to see if it will stick. We are doing the ground work for more trials it seems but do we really want to do more? How close are we now to knowing the results of the 70 patients? 5 weeks? 6 weeks? Less? More? Only time will tell. It is our fastest path in the USA for an EUA. Let’s hope for the best and not dwell on the past. We have things to look forward to. Looking back isn’t the brightest picture for t he longs. I know because when I invested the HIV BLA was suppose to be files in a month in Sept. 2019. That didn’t happen. It took until June 2020. Then you know the rest of the story.
This was no way directed at you Bored Lawyer... I agreed then went much further than I thought I would. It always seems like I have much to say. Sorry...
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Top 5 Most Recently Viewed Articles
Introducing Gabelli's Fully Transparent ETF Strategies Gabelli Funds, LLC has embarked on an exciting new chapter by making all of its actively managed exchange-traded funds (ETFs) fully transparent. This progressive move enhances accessibility for both advisors and investors, aligning with the firm’s fundamental investment philosophy of bottom-up research. Gabelli’s...
Continue Reading
Bitcoin Reaches New All-Time High Bitcoin, the leading cryptocurrency in the market, has recently surged to a remarkable record high approaching $95,000. This significant price spike follows reports suggesting potential collaborations that may pave the way for a more favorable environment for cryptocurrencies in the financial landscape. Market Reactions and Implications...
Continue Reading
Manpower Recognized Among Industry Leaders Manpower, a global leader in staffing and workforce solutions, has recently earned a notable accolade by being named a Leader in the Everest Group's 2024 U.S. Contingent Talent and Strategic Solutions PEAK Matrix Assessment. This recognition underscores the company's commitment to excellence and innovation in the staffing...
Continue Reading
The Rising FIBC Market: An Overview The global Flexible Intermediate Bulk Container (FIBC) market is on a promising growth trajectory, with projections indicating an increase in market valuation from USD 7.4 billion in the near future to an impressive USD 11.5 billion by the year 2035. This growth reflects a compound annual growth rate (CAGR) of 4.5% from now to 2035,...
Continue Reading
Real Matters Reports Impressive Q3 Financial Results (All amounts are expressed in millions of U.S. dollars, excluding per share amounts, unless otherwise stated.) TORONTO – Real Matters Inc. (TSX: REAL), a leader in providing network management services for the mortgage and insurance sectors, has announced its financial results for the third quarter, showcasing a...
Continue Reading